secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2021-09-30T23:59:59+00:00
Accession:  0001213900-21-050817
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx appoints Edward Stelmakh CFO/COO; Doug Baker transitions to EVP of finance
--------------------------------------------------------------------------------

- Edward Stelmakh named CFO/COO effective Oct 11, 2021; Doug Baker becomes EVP of finance and accounting.
- Stelmakh's annual base salary set at $425,000; target bonus 50% of base; one-time equity grant valued at $3.0 million.
- Stelmakh brings 30+ years pharma experience, most recently as CFO/COO at Otsuka America Pharmaceuticals.
- Severance includes 12 months base salary if terminated without cause, plus COBRA coverage for 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/0001213900-21-050817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/ea148140-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-050817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer